Open AccessEfficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
Author(s) -
Éric Bruckert,
Sonia Caprio,
Albert Wiegman,
MinJi Charng,
Cézar A. Zárate-Morales,
Marie T. BaccaraDinet,
Garen Manvelian,
Anne Ourliac,
Michel Scemama,
Stephen R. Daniels
Publication year - 2022
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.122.317793
Subject(s) - alirocumab , tolerability , pcsk9 , familial hypercholesterolemia , medicine , clinical endpoint , ldl receptor , gastroenterology , kexin , endocrinology , lipoprotein , adverse effect , cholesterol , clinical trial , apolipoprotein a1
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom